title: [Correlation between the expression of Pim-1 and androgen-deprivation therapy for prostate cancer].
abstract: OBJECTIVE
  To investigate the expression of the Pim-1 gene in the LNCaP cells of the animal model of orthotopically implanted prostate cancer by surgical castration simulating androgen-deprivation therapy.
  
  
  METHODS
  We equally allocated 32 male BALBc-nu mice into 4 groups, androgen-dependent prostate cancer (ADPC), androgen-deprivation therapy (ADT) , castration-resistant prostate cancer (CRPC) and blank control, and established the models of orthotopically implanted tumor using human prostate cancer LNCaP cells. We detected and ,compared the expressions of Pim-1, PSA, and androgen receptor (AR) in the tumor tissues of different groups by RT-PCR. qRT-PCR, ELSIA and immunohistochemistry.
  
  
  RESULTS
  The relative gray scales in the ADPC and CRPC groups were 0.59 ± 0.01 and 1.14 ± 0.02, with statistically significant differences from 0.62 ± 0.03 in the ADT group (P < 0.05), and the Δ Ct values of Pim-1 were 6.15 ± 0.34 and 4.56 ± 0.23 in the former two groups, also with significant differences from 5.11 ± 0.21 in the latter (P < 0.05). The results of 2-ΔΔ Ct relative quantification analysis showed that the amplification products of Pim-1 in the ADT and CRPC groups increased 2.05 and 3.01 times respectively that of the ADPC group. The concentration of PSA was significantly higher in the ADPC ([480 ± 25] pg/ml) and CRPC ([870 ± 23] pg/ml) than in the ADT ([170 ± 32] pg/ml) and blank control groups (0 µg/L) (P < 0.01). The mean optical densities of Pim-1 and AR proteins were 0.017 ± 0.002 and 0.032 ± 0.009 in the ADPC group and 0.024 ± 0.002 and 0.040 ± 0.011 in the CRPC group, both with significant differences from those in the ADT group (0.018 ± 0.001 and 0.019 ± 0.006) (P < 0.01).
  
  
  CONCLUSIONS
  Pim-1 is highly expressed in nude mice with prostate cancer receiving androgen-deprivation therapy and plays an important role in the progression and metastasis of prostate cancer.
authors.forename: Jiang
authors.initials: J
authors.lastname: Wang
authors.forename: Chang-yi
authors.initials: CY
authors.lastname: Quan
authors.forename: Wen-liang
authors.initials: WL
authors.lastname: Chang
authors.forename: Zhi-qun
authors.initials: ZQ
authors.lastname: Shang
authors.forename: Ning
authors.initials: N
authors.lastname: Jiang
authors.forename: Bo
authors.initials: B
authors.lastname: Li
authors.forename: Yuan-jie
authors.initials: YJ
authors.lastname: Niu
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D000818:Animals; D018450:Disease Progression; D015870:Gene Expression; D064593:Heterografts; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009376:Neoplasms, Hormone-Dependent / Q000378:metabolism; D017430:Prostate-Specific Antigen / Q000378:metabolism; D064129:Prostatic Neoplasms, Castration-Resistant / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D051573:Proto-Oncogene Proteins c-pim-1 / Q000378:metabolism*; D011944:Receptors, Androgen / Q000378:metabolism
chemical_list: D000726:Androgen Antagonists; D011944:Receptors, Androgen; C496636:Pim1 protein, mouse; D051573:Proto-Oncogene Proteins c-pim-1; D017430:Prostate-Specific Antigen